查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771491

全球微殘留疾病檢測市場：市場規模、佔有率、趨勢分析（按技術、癌症類型、最終用途和地區）、細分市場預測（2025-2030 年）

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Cancer Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10個工作天內

價格

微殘留疾病檢測市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球微小殘留疾病檢測市場規模預計到2030年將達到45億美元，2025年至2030年的複合年成長率為10.1%。

MRD檢測作為一種新型的診斷和預後評估方法，將有助於精準制定治療方法，以治療各類骨髓惡性腫瘤。治療結果的評估對於指定癌症治療制度的成功實施至關重要。

MRD 產生的分子資訊對於更好地理解癌症病理並最終最佳化治療效果至關重要。因此，MRD 檢測擴大被用作眾多腫瘤學臨床試驗的終點分析步驟，並且還能有效記錄個體基因特徵導致的治療結果差異。例如，2020 年 11 月，Adaptive Biotechnologies Corporation 與葛蘭素史克公司合作，使用 clonoSEQ 檢測方法評估葛蘭素史克血液學藥物治療後殘留的癌細胞。

手術切除腫瘤並結合其他相關療法並不一定意味著癌細胞被完全清除。癌細胞的痕跡可能殘留在身體的某些部位和血液中。診斷這些殘留細胞對於確定是否需要進一步化療或放射線治療至關重要。研究人員正在設計能夠有效偵測MRD的非侵入性檢測方法。例如，2022年2月，C2i Genomics公司的一項血液檢測對腫瘤外科手術後殘留的癌細胞進行了定量分析。這項C2inform檢測也已獲得CE標誌認證，並在歐洲以「軟體即醫療設備」MRD檢測的形式提供。

癌症藥物可根據相關臨床證據進行有效客製化，避免癌細胞滯留，並根據個體的具體進展進行個體化治療。大量研究支持考慮個體基因特徵以獲得有效治療。例如，2022年10月，Adaptive Biotechnologies Corporation與Epic合作，以增加血癌患者MRD監測的可近性。此外，2021年2月，Natera Inc.與Personalis Inc.合作，透過整合NeXT腫瘤分析（由Personalis生產）和個人化ctDNA平台Signatera診斷產品（由Natera, Inc.生產），有效地設計治療監測方案並評估MRD，從而了解個人化癌症治療的效果。

微殘留疾病檢測市場報告重點

  • 從技術角度來看，由於流式細胞技術檢測具有高靈敏度和廣泛的適用性，2024 年流式細胞儀在微小殘留疾病檢測市場中佔據主導地位。
  • 根據癌症類型，由於骨髓惡性腫瘤盛行率不斷上升，骨髓惡性腫瘤在 2024 年佔據了市場主導地位，收益佔有率為 68.58%。
  • 根據最終用途，醫院和專科診所將成為 2024 年產生最高收益的部分。
  • 由於報銷制度的改善以及該地區骨髓惡性腫瘤的盛行率不斷上升，預計 2024 年北美將在微小殘留疾病檢測市場佔據主導地位。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 微殘留疾病檢測市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 微殘留疾病檢測市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章微殘留疾病檢測市場：依技術分類的估計與趨勢分析

  • 按技術分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球微殘留病檢測市場展望（按技術）
  • 市場規模預測及趨勢分析（2018年及2030年）
    • 流式細胞技術
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 其他

第5章微殘留疾病檢測市場：按癌症類型估計和趨勢分析

  • 癌症類型市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球微殘留疾病檢測市場：癌症類型展望
  • 市場規模預測及趨勢分析（2018年及2030年）
    • 造血系統惡性腫瘤
    • 固態腫瘤

第6章微殘留疾病檢測市場：依最終用途的估計與趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球微小殘留疾病檢測市場：依最終用途分類的展望
  • 市場規模預測及趨勢分析（2018年及2030年）
    • 醫院和專科診所
    • 學術研究所
    • 診斷實驗室
    • 其他

第7章微殘留疾病檢測市場：區域估計與趨勢分析

  • 按技術分類的市場佔有率（2024 年和 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018年及2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Exact Sciences Corporation.
    • GRAIL, LLC
    • Veracyte, Inc.
    • Natera, Inc.
    • Guardant Health
    • F. Hoffmann-La Roche Ltd
    • FOUNDATION MEDICINE, INC.
    • QIAGEN
    • mdxhealth
    • Bio-Techne.
Product Code: GVR-4-68040-016-3

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is estimated to reach USD 4.50 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

  • By technology, the flow cytometry segment held a dominant share in the minimal residual disease testing market in 2024, owing to the high sensitivity and wide applicability of MRD testing.
  • By cancer type, the hematological malignancy cancer dominated the market with a revenue share of 68.58% in 2024, owing to the increasing prevalence of hematological malignancy.
  • By end-use, the hospitals and specialty clinics segment is the highest revenue-generating segment in 2024, owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics.
  • North America dominated the minimal residual disease testing market in 2024, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Cancer Type
    • 1.2.3. End use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology Outlook
    • 2.2.2. Test Type Outlook
    • 2.2.3. Cancer Type Outlook
    • 2.2.4. End use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Minimal Residual Disease Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Flow Cytometry
      • 4.4.1.1. Flow Cytometry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Polymerase Chain Reaction (PCR)
      • 4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Next Generation Sequencing (NGS)
      • 4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hematological Malignancy
      • 5.4.1.1. Hematological Malignancy market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Leukemia
        • 5.4.1.2.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Lymphoma
        • 5.4.1.3.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Solid Tumors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Minimal Residual Disease Testing Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Minimal Residual Disease Testing Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Specialty Clinics
      • 6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Academic and Research Institutes
      • 6.4.2.1. Academic and Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Diagnostic Laboratories
      • 6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Exact Sciences Corporation.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GRAIL, LLC
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Veracyte, Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Natera, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Guardant Health
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F. Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. FOUNDATION MEDICINE, INC.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. QIAGEN
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. mdxhealth
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Bio-Techne.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 7 Global Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 13 U.S Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 19 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 23 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 27 UK Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 29 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 33 France Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 38 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 41 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 44 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 46 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 47 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 54 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 55 Japan Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 58 China Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 60 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 61 India Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 66 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 67 Australia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 73 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Minimal Residual Disease Testing: market outlook
  • Fig. 14 Minimal Residual Disease Testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Minimal Residual Disease Testing driver impact
  • Fig. 20 Minimal Residual Disease Testing restraint impact
  • Fig. 21 Minimal Residual Disease Testing strategic initiatives analysis
  • Fig. 22 Minimal Residual Disease Testing: Technology movement analysis
  • Fig. 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
  • Fig. 24 Flow Cytometry market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 26 Next Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 28 Minimal Residual Disease Testing: Cancer movement analysis
  • Fig. 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
  • Fig. 30 Hematological Malignancy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 31 Leukemia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 32 Lymphoma market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 33 Solid Tumors market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 34 Minimal Residual Disease Testing: End use movement analysis
  • Fig. 35 Minimal Residual Disease Testing: End use outlook and key takeaways
  • Fig. 36 Hospitals & Specialty Clinics market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 37 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 38 Academic and Research Institutions market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 40 Global minimal residual disease testing market: Regional movement analysis
  • Fig. 41 Global minimal residual disease testing market: Regional outlook and key takeaways
  • Fig. 42 Global minimal residual disease testing market shares and leading players
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 57 France
  • Fig. 58 France market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 66 Sweden
  • Fig. 67 Sweden market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 68 Norway
  • Fig. 69 Norway market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 70 Asia Pacific
  • Fig. 71 Asia Pacific market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 72 China
  • Fig. 73 China market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 74 Japan
  • Fig. 75 Japan market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 76 India
  • Fig. 77 India market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 101 Market share of key market players- Minimal Residual Disease Testing